Arthneeti

Indo US Bio-Tech Q2 FY27 Share Price & Earnings Call Analysis

₹66.31-2.41% today
Market cap
₹133 Cr
P/E
30.64
ROE
15.34%
PEG
1.40
Price to sales
1.37
Debt to equity
0.48
52W high / low
₹151 / ₹60.3
Sales growth (5Y)
22.91%
EBITDA margin
9.02%
Net profit margin
11.88%
Promoter holding
68.29%
Sales (last year)
₹97 Cr

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Indo US Bio-Tech rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Financials of Indo US Bio-Tech

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Indo US Bio-Tech

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +70.17%70.18%70.18%70.18%70.18%70.18%70.18%70.18%70.18%68.29%68.29%68.29%
FIIs +0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.18%0.01%0.01%
DIIs +0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.25%
Public +29.83%29.83%29.82%29.83%29.82%29.83%29.83%29.83%29.83%31.53%31.70%31.46%
No. of Shareholders1,2271,1661,1339712,8282,7803,1124,1304,7384,5314,6904,629

Financials of Indo US Bio-Tech

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +15.8122.1115.7724.7222.1723.5633.3830.7730.8522.8026.0232.9915.05
Expenses +13.2117.8814.7921.0317.0518.0228.8025.3026.6918.6522.7929.0217.66
Operating Profit2.604.230.983.695.125.544.585.474.164.153.233.97-2.61
OPM %16.45%19.13%6.21%14.93%23.09%23.51%13.72%17.78%13.48%18.20%12.41%12.03%-17.34%
Other Income +0.000.080.210.030.020.020.120.000.030.010.020.120.05
Interest0.410.370.360.330.520.380.260.450.420.770.600.740.81
Depreciation0.210.190.200.200.180.160.560.200.210.220.270.270.28
Profit before tax1.983.750.633.194.445.023.884.823.563.172.383.08-3.65
Tax %15.66%1.87%17.46%0.63%2.03%-0.80%4.90%2.49%3.09%5.36%17.23%1.30%0.55%
Net Profit +1.673.680.523.174.365.053.684.703.453.001.973.04-3.67
EPS in Rs0.831.840.261.582.172.521.842.341.721.500.981.52-1.83

Financials of Indo US Bio-Tech

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +19.5819.0224.2629.4035.3539.7639.3749.3860.8472.84103.84110.4496.86
Expenses +18.9818.5223.0226.6931.9135.7833.8342.4351.4562.0584.9093.4388.12
Operating Profit0.600.501.242.713.443.985.546.959.3910.7918.9417.018.74
OPM %3.06%2.63%5.11%9.22%9.73%10.01%14.07%14.07%15.43%14.81%18.24%15.40%9.02%
Other Income +0.090.100.070.220.03-0.010.030.180.020.320.180.050.20
Interest0.320.220.640.720.400.881.181.201.201.521.492.242.92
Depreciation0.110.140.150.170.250.230.260.440.830.801.100.901.04
Profit before tax0.260.240.522.042.822.864.135.497.388.7916.5313.924.98
Tax %-92.31%-50.00%25.00%28.92%25.53%11.54%-23.49%4.55%2.03%6.37%1.57%5.75%
Net Profit +0.500.360.401.452.092.535.105.247.248.2416.2713.124.34
EPS in Rs0.480.350.381.411.441.743.522.863.604.118.116.542.17
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Indo US Bio-Tech

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital1.491.491.493.424.856.076.079.1710.0320.0520.0520.0520.05
Reserves1.411.772.001.529.0510.3715.4729.7144.4742.7058.4772.4871.85
Borrowings +1.694.684.856.546.178.5811.4812.5011.6014.3314.8437.0344.17
Other Liabilities +3.095.744.205.673.819.6810.664.193.377.384.493.544.26
Total Liabilities7.6813.6812.5417.1523.8834.7043.6855.5769.4784.4697.85133.10140.33
Fixed Assets +1.091.061.211.501.371.412.335.547.376.6910.2311.2211.19
CWIP0.000.000.000.001.171.281.992.321.373.780.000.501.03
Investments0.000.000.000.000.000.000.010.010.000.000.000.000.00
Other Assets +6.5912.6211.3315.6521.3432.0139.3547.7060.7373.9987.62121.38128.11
Total Assets7.6813.6812.5417.1523.8834.7043.6855.5769.4784.4697.85133.10140.33

Financials of Indo US Bio-Tech

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0.07-0.88-3.17-0.840.222.910.532.221.42-12.58
Cash from Investing Activity +-0.170.31-2.56-0.57-1.75-5.40-6.67-2.53-0.79-1.50
Cash from Financing Activity +0.050.595.741.531.462.416.291.22-1.4819.96
Net Cash Flow-0.050.020.010.12-0.07-0.080.140.91-0.855.88
Free Cash Flow-0.10-1.33-4.46-1.21-1.68-1.06-1.29-0.390.56-14.99
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit11%-16%-92%-20%6%47%9%23%9%-71%

Financials of Indo US Bio-Tech

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days24.61107.2776.13111.6193.55192.60228.90151.82148.4295.4652.7345.48
Inventory Days90.92117.8492.1598.01176.09750.51
Days Payable56.63115.4164.1371.4533.87666.84
Cash Conversion Cycle58.89109.70104.15138.17235.77276.26228.90151.82148.4295.4652.7345.48
Working Capital Days66.3632.6233.5559.34128.55137.43185.79257.23284.55266.23246.51248.04
ROCE %13.94%7.34%14.25%27.85%20.41%16.68%18.33%15.85%14.61%14.40%21.15%14.50%

Continue your research

What Indo US Bio-Tech's management said in earlier quarters